 "AstraZeneca Pharma India Q3 net profit declines 21% at Rs 21 crore")
Drug firmAstraZeneca Pharma India on Monday reported a 21 per cent decline in net profit at Rs 21.05 crore for the quarter ended in December.
The company had posteda net profitof Rs 26.70 crore for the corresponding period of the previous fiscal,AstraZeneca Pharma India said in a BSE filing.
Revenue from operations of the company stood at Rs 200.25 crore for the quarter under consideration. It was Rs 223.86 crore for the same period a year ago, it added.
Shares ofAstraZeneca Pharma India closed at Rs3,899.40per scrip on BSE, up0.11 percent from its previous close.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app